Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 8/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.38 |
| ▸ | CBFB | Q13951 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2624385 | 0.86 | PDK1 (0.53) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31003221 | 0.83 | PDK1 (0.50) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21008350 | 0.80 | POLB (0.53) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12241716 | 0.78 | POLB (0.54) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4929686 | 0.78 | PDK1 (0.45) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21275558 | 0.73 | LOXL2 (0.62) | PDK1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29390917 | 0.72 | PDK1 (0.58) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2176039 | 0.72 | PDK1 (0.58) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15221711 | 0.71 | POLB (0.62) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26485577 | 0.71 | POLB (0.50) | PDK1POLBNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385019-B2 | Inhibitors of EGFR and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385019-B2 | Inhibitors of EGFR and methods of use thereof | EGFR, ERBB2, ERBB3 | PDK1 1715/4885POLB 1318/4885NPC1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.